Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D
Wiener klinische Wochenschrift · 2026-11 · 138 (21-22) · 697-700
DOI: 10.1007/s00508-026-02748-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 11.06.2026. Verfasst von Mathias Jachs und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Währinger Guertel 18-20, 1090, Vienna, Austria…. Hauptthemen laut MEDLINE: Hypertension, Portal, Hepatitis D, Chronic, Antiviral Agents, Liver Cirrhosis. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Treatment options for chronic hepatitis D (CHD) are limited in patients who do not respond to recommended treatment with bulevirtide ± pegylated interferon. The use of REP 2139-Mg is a novel treatment option that has recently demonstrated efficacy and safety in phase 2 trials and a compassionate access program that included three patients treated at the Vienna General Hospital with compensated advanced chronic liver disease and clinically significant portal hypertension (CSPH). Long-term outcome of CSPH patients treated with REP 2139-Mg is unknown; thus, surrogate endpoints are of interest in this population. In the 3 patients receiving REP 2139-Mg for 12 months at our center, we monitored the hepatic venous pressure gradient (HVPG) as the strongest prognostic surrogate biomarker in compensated cirrhosis at baseline, and after 3 and 12 months of treatment. The HVPG dynamics alongside additional liver function tests observed are summarized in this report and two out of three patients achieved undetectable hepatitis-D-virus(HDV)-RNA and low hepatitis B surface Antigen (HBsAg) following pronounced alanine aminotransferase (ALT) flares during REP 2139-Mg treatment. The first patient showed virologic non-response and no HVPG dynamics during treatment. The second patient developed jaundice upon treatment initiation, resulting in a transient increase in HVPG despite virologic response. The third patient achieved virologic response that was paralleled by sustained reductions in HVPG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Währinger Guertel 18-20, 1090, Vienna, Austria. mattias.jachs@meduniwien.ac.at.
- Vienna Hepatic Hemodynamic Lab, Department of Medicine III, Medical University of Vienna, Vienna, Austria. mattias.jachs@meduniwien.ac.at.
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Währinger Guertel 18-20, 1090, Vienna, Austria.
- Vienna Hepatic Hemodynamic Lab, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Universitätsklinikum St. Pölten, St. Pölten, Austria.
- Replicor Inc., Montreal, Canada.
Förderung
- Medical University of Vienna
Zitieren
APA
Jachs, M., Schwarz, M., Mandorfer, M., Vaillant, A., & Reiberger, T. (2026). Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D. Wiener klinische Wochenschrift, 138(21-22), 697-700. https://doi.org/10.1007/s00508-026-02748-2
Vancouver
Jachs M, Schwarz M, Mandorfer M, Vaillant A, Reiberger T. Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D. Wiener klinische Wochenschrift. 2026;138(21-22):697-700. doi:10.1007/s00508-026-02748-2
BibTeX
@article{Jachs2026,
author = {Jachs, Mathias and Schwarz, Michael and Mandorfer, Mattias and Vaillant, Andrew and Reiberger, Thomas},
title = {Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D},
journal = {Wiener klinische Wochenschrift},
year = {2026},
volume = {138},
number = {21-22},
pages = {697--700},
doi = {10.1007/s00508-026-02748-2}
}
EUVIMED